Trials / Completed
CompletedNCT03964298
Study of the Activity of PD-1 Inhibitors in Metastatic Uveal Melanoma
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 100 (actual)
- Sponsor
- Institut Curie · Academic / Other
- Sex
- All
- Age
- —
- Healthy volunteers
- —
Summary
Study of the activity of PD-1 inhibitors in metastatic uveal melanoma
Detailed description
The aim of the research is to study the activity of PD-1 inhibitors in patients with metastatic uveal melanoma and treated by Nivolumab and Pembrolizumab. These molecules have already received the authorities approvals. The data collected will be crucial for the understanding of the mechanism of PD-1 inhibitors and also for the futures studies.
Conditions
Timeline
- Start date
- 2016-11-01
- Primary completion
- 2019-11-01
- Completion
- 2020-12-01
- First posted
- 2019-05-28
- Last updated
- 2025-08-11
Locations
1 site across 1 country: France
Source: ClinicalTrials.gov record NCT03964298. Inclusion in this directory is not an endorsement.